Get the Stockscreener App
9.97
6.91%
-0.74
After Hours:
10.46
0.49
+4.91%
Oric Pharmaceuticals Inc stock is traded at $9.97, with a volume of 893.66K.
It is down -6.91% in the last 24 hours and down -1.77% over the past month.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
See More
Previous Close:
$10.71
Open:
$10.63
24h Volume:
893.66K
Relative Volume:
0.69
Market Cap:
$849.69M
Revenue:
-
Net Income/Loss:
$-119.87M
P/E Ratio:
-5.5083
EPS:
-1.81
Net Cash Flow:
$-109.90M
1W Performance:
-15.00%
1M Performance:
-1.77%
6M Performance:
-4.32%
1Y Performance:
-10.98%
1-Day Range:
$9.88
$10.76
1-Week Range:
$9.88
$11.69
52-Week Range:
$3.8951
$14.67
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
Name
Oric Pharmaceuticals Inc
Sector
Industry
Phone
(650) 388-5600
Address
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Compare ORIC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
9.97 | 912.69M | 0 | -119.87M | -109.90M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-08-25 | Initiated | Ladenburg Thalmann | Buy |
| Oct-31-24 | Initiated | Wells Fargo | Overweight |
| Sep-06-24 | Initiated | Stifel | Buy |
| Feb-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-22-23 | Initiated | Wedbush | Outperform |
| Mar-23-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-21-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-16-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-18-22 | Resumed | Oppenheimer | Perform |
| Apr-04-22 | Upgrade | Citigroup | Neutral → Buy |
| Mar-25-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-22-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-22-22 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-06-21 | Upgrade | Citigroup | Neutral → Buy |
| Jan-25-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-13-20 | Initiated | Robert W. Baird | Outperform |
| Aug-06-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| May-19-20 | Initiated | Citigroup | Neutral |
| May-19-20 | Initiated | Guggenheim | Buy |
| May-19-20 | Initiated | JP Morgan | Overweight |
| May-19-20 | Initiated | Jefferies | Buy |
View All
Oric Pharmaceuticals Inc Stock (ORIC) Latest News
Is ORIC Pharmaceuticals Inc. a candidate for recovery playMarket Timing Strategy with Technical Filters - Newser
Can swing trading help recover from ORIC Pharmaceuticals Inc. lossesBuy Signal Forecast With Short-Term Data - Newser
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Price momentum metrics for ORIC Pharmaceuticals Inc. explainedRisk Balanced Picks for Safer Trading - Newser
How to forecast ORIC Pharmaceuticals Inc. trends using time seriesTrade Setup Builder with Custom Alerts - Newser
New York State Common Retirement Fund Acquires 22,257 Shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
Is ORIC Pharmaceuticals Inc. a Top Dividend Stock to Watch in 2025Free Weekly Watchlist of High Movers - Newser
Oric Pharmaceuticals (NASDAQ:ORIC) Shares Down 8.2%Here's What Happened - MarketBeat
ORIC Pharmaceuticals Inc. stock momentum explainedFree High Conviction Intraday Stock Signals - Newser
What data driven models say about ORIC Pharmaceuticals Inc.’s futureFree Trade Ready Stock Watch for Short Term - Newser
Visualizing ORIC Pharmaceuticals Inc. stock with heatmapsFree Stock Market Entry Timing Signals - Newser
Moving Average Trends for ORIC Pharmaceuticals Inc. Stock: What They IndicatePrice Forecast Based on AI Analysis - Newser
Why ORIC Pharmaceuticals Inc. stock attracts strong analyst attentionHigh Accuracy Entry Strategy Analysis - beatles.ru
Will ORIC Pharmaceuticals Inc. continue its uptrendFree Consistent Profit Pattern Recognition Tools - Newser
What makes ORIC Pharmaceuticals Inc. stock price move sharplyMarket Ready Picks with Technical Support - Newser
Can volume confirm reversal in ORIC Pharmaceuticals Inc.Free Low Risk Equity Screener With Results - Newser
What catalysts could drive ORIC Pharmaceuticals Inc. stock higher in 2025Dynamic investment growth - jammulinksnews.com
What data driven models say about ORIC Pharmaceuticals Inc.’s future Asset Safety Selection Using Quantitative Analysis - Newser
How ORIC Pharmaceuticals Inc. stock performs during market volatility Equity Portfolio Outlook and Performance Summary - Newser
ORIC Pharmaceuticals Inc. stock momentum explained Free Community Verified Stock Suggestions - Newser
What is the risk reward ratio of investing in ORIC Pharmaceuticals Inc. stockAchieve unparalleled market performance - jammulinksnews.com
How ORIC Pharmaceuticals Inc. stock performs during market volatilityFree Stock Market Watch With Alerts - Newser
Is ORIC Pharmaceuticals Inc. Stock a Smart Buy in 2025 Investment Analysis InsideMomentum Buy Alert - metal.it
Competitive Positioning of ORIC Pharmaceuticals Inc.: Is It Leading or LaggingFree Smart Money Stock Analysis - Newser
New York State Common Retirement Fund Has $215,000 Stock Position in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
Can ORIC Pharmaceuticals Inc. stock recover from recent declineBreakthrough profit margins - jammulinksnews.com
What drives ORIC Pharmaceuticals Inc. stock priceUnprecedented growth rates - PrintWeekIndia
ORIC Pharmaceuticals Inc. Stock Analysis and ForecastTriple-digit wealth increases - Autocar Professional
What analysts say about ORIC Pharmaceuticals Inc. stockFree Smart Trading Workshop - Autocar Professional
Arizona State Retirement System Invests $56,000 in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
Is ORIC Pharmaceuticals Inc. a good long term investmentFree Trading Psychology Coaching - jammulinksnews.com
Oric Pharmaceuticals Inc Stock (ORIC) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):